Baidu
map

Ann Surg:直肠癌根治性切除术前输血不影响患者生存率

2013-03-21 ecoliDH5 丁香园

患者整体生存率曲线 对于术前输血是否会对患者生存产生不利影响,仍存在较大争议。对此,瑞士圣加伦州立医院的Ignazio Tarantino博士等人通过倾向分数法,评价了术前输血对接受根治性切除术治疗的I-III期直肠癌患者整体生存率及无病生存率的可能影响。该研究结果发表于2013年3月6日在线出版的《外科学年鉴》(Annals of Surgery)杂志上。 该单中心研究对401例I-II


患者整体生存率曲线
对于术前输血是否会对患者生存产生不利影响,仍存在较大争议。对此,瑞士圣加伦州立医院的Ignazio Tarantino博士等人通过倾向分数法,评价了术前输血对接受根治性切除术治疗的I-III期直肠癌患者整体生存率及无病生存率的可能影响。该研究结果发表于2013年3月6日在线出版的《外科学年鉴》(Annals of Surgery)杂志上。
该单中心研究对401例I-III期直肠癌患者进行了评价,这些患者于1996年至2008年接受开腹根治性切除术治疗。研究中位随访时间为34.2个月。研究人员通过Cox回归方法及倾向分数法,对未接受术前输血的患者进行了对比。
共有217例(54.1%)患者进行了输血。研究结果表明,在输血方面,患者特征呈高度偏倚性(偏倚分数,0.77 ± 0.23 vs. 0.28 ± 0.25; P < 0.001)。未经校正的分析结果表明,输血与119%的死亡率风险增加有关(风险比 (HR): 2.19, 95% 置信区间 (CI): 1.34-3.57, P = 0.001)。而经倾向分数校正后,Cox回归结果(HR: 0.86, 95% CI: 0.60-1.23, P = 0.672)表明,输血与复发风险增加无关。
该研究通过倾向分数法相关分析的有力证据首次证明,接受根治性直肠癌切除术治疗的患者,术前输血可造成较差的肿瘤结局,这由需要输血的临床环境造成,而非输血本身造成。因此,在对接受根治性直肠癌切除治疗的患者进行术前输血决策时,整体生存率及无病生存相关关注不应成为影响决策的因素。

Objective
To assess the putative impact of perioperative blood transfusions on overall and disease-free survival in patients undergoing curative resection of stage I-III rectal cancer by applying propensity-scoring methods.
Background
Whether perioperative blood transfusions negatively impact survival remains a matter of great debate.
Methods
In a single-center study, 401 patients undergoing open curative resection of stage I-III rectal cancer between 1996 and 2008 were assessed. The median follow-up was 34.2 months. Patients who did and did not receive perioperative blood transfusions were compared using Cox regression and propensity score analyses.
Results
Overall, 217 patients (54.1%) received blood transfusions. Patients' characteristics were highly biased concerning transfusions (propensity score 0.77 +/- 0.23 vs. 0.28 +/- 0.25; P < 0.001). In unadjusted analysis, blood transfusions were associated with a 119% increased risk of mortality [hazard ratio (HR): 2.19, 95% confidence interval (CI): 1.34-3.57, P = 0.001]. In propensity score-adjusted Cox regression (HR: 1.02, 95% CI: 0.65-1.58, P = 0.970), blood transfusions did not increase the risk of overall survival. Similarly, in propensity score-adjusted Cox regression (HR: 0.86, 95% CI: 0.60-1.23, P = 0.672), blood transfusions were not associated with an increased risk of recurrence.
Conclusions
This is the first propensity score-based analysis providing compelling evidence that worse oncological outcomes after curative rectal cancer resection in patients receiving perioperative blood transfusions are caused by the clinical circumstances requiring transfusions, not due to the blood transfusions themselves. Therefore, concerns about overall and disease-free survival should be no issue in the decision-making regarding perioperative blood transfusions in patients undergoing curative rectal cancer resection.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1876632, encodeId=bdbc18e663225, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sun Jun 23 08:16:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932456, encodeId=da6b193245676, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Jan 22 13:16:00 CST 2014, time=2014-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256455, encodeId=0283125645522, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat Mar 23 05:16:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259627, encodeId=df31125962e5b, content=<a href='/topic/show?id=569c9382389' target=_blank style='color:#2F92EE;'>#输血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93823, encryptionId=569c9382389, topicName=输血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Mar 23 05:16:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517614, encodeId=a480151e614d0, content=<a href='/topic/show?id=e8f46222188' target=_blank style='color:#2F92EE;'>#根治性切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62221, encryptionId=e8f46222188, topicName=根治性切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343211090953, createdName=12498f6em10暂无昵称, createdTime=Sat Mar 23 05:16:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586002, encodeId=392e1586002fb, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Mar 23 05:16:00 CST 2013, time=2013-03-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1876632, encodeId=bdbc18e663225, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sun Jun 23 08:16:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932456, encodeId=da6b193245676, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Jan 22 13:16:00 CST 2014, time=2014-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256455, encodeId=0283125645522, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat Mar 23 05:16:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259627, encodeId=df31125962e5b, content=<a href='/topic/show?id=569c9382389' target=_blank style='color:#2F92EE;'>#输血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93823, encryptionId=569c9382389, topicName=输血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Mar 23 05:16:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517614, encodeId=a480151e614d0, content=<a href='/topic/show?id=e8f46222188' target=_blank style='color:#2F92EE;'>#根治性切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62221, encryptionId=e8f46222188, topicName=根治性切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343211090953, createdName=12498f6em10暂无昵称, createdTime=Sat Mar 23 05:16:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586002, encodeId=392e1586002fb, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Mar 23 05:16:00 CST 2013, time=2013-03-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1876632, encodeId=bdbc18e663225, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sun Jun 23 08:16:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932456, encodeId=da6b193245676, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Jan 22 13:16:00 CST 2014, time=2014-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256455, encodeId=0283125645522, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat Mar 23 05:16:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259627, encodeId=df31125962e5b, content=<a href='/topic/show?id=569c9382389' target=_blank style='color:#2F92EE;'>#输血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93823, encryptionId=569c9382389, topicName=输血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Mar 23 05:16:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517614, encodeId=a480151e614d0, content=<a href='/topic/show?id=e8f46222188' target=_blank style='color:#2F92EE;'>#根治性切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62221, encryptionId=e8f46222188, topicName=根治性切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343211090953, createdName=12498f6em10暂无昵称, createdTime=Sat Mar 23 05:16:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586002, encodeId=392e1586002fb, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Mar 23 05:16:00 CST 2013, time=2013-03-23, status=1, ipAttribution=)]
    2013-03-23 guoyibin
  4. [GetPortalCommentsPageByObjectIdResponse(id=1876632, encodeId=bdbc18e663225, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sun Jun 23 08:16:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932456, encodeId=da6b193245676, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Jan 22 13:16:00 CST 2014, time=2014-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256455, encodeId=0283125645522, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat Mar 23 05:16:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259627, encodeId=df31125962e5b, content=<a href='/topic/show?id=569c9382389' target=_blank style='color:#2F92EE;'>#输血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93823, encryptionId=569c9382389, topicName=输血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Mar 23 05:16:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517614, encodeId=a480151e614d0, content=<a href='/topic/show?id=e8f46222188' target=_blank style='color:#2F92EE;'>#根治性切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62221, encryptionId=e8f46222188, topicName=根治性切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343211090953, createdName=12498f6em10暂无昵称, createdTime=Sat Mar 23 05:16:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586002, encodeId=392e1586002fb, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Mar 23 05:16:00 CST 2013, time=2013-03-23, status=1, ipAttribution=)]
    2013-03-23 windight
  5. [GetPortalCommentsPageByObjectIdResponse(id=1876632, encodeId=bdbc18e663225, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sun Jun 23 08:16:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932456, encodeId=da6b193245676, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Jan 22 13:16:00 CST 2014, time=2014-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256455, encodeId=0283125645522, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat Mar 23 05:16:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259627, encodeId=df31125962e5b, content=<a href='/topic/show?id=569c9382389' target=_blank style='color:#2F92EE;'>#输血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93823, encryptionId=569c9382389, topicName=输血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Mar 23 05:16:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517614, encodeId=a480151e614d0, content=<a href='/topic/show?id=e8f46222188' target=_blank style='color:#2F92EE;'>#根治性切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62221, encryptionId=e8f46222188, topicName=根治性切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343211090953, createdName=12498f6em10暂无昵称, createdTime=Sat Mar 23 05:16:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586002, encodeId=392e1586002fb, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Mar 23 05:16:00 CST 2013, time=2013-03-23, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1876632, encodeId=bdbc18e663225, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sun Jun 23 08:16:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932456, encodeId=da6b193245676, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Jan 22 13:16:00 CST 2014, time=2014-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256455, encodeId=0283125645522, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat Mar 23 05:16:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259627, encodeId=df31125962e5b, content=<a href='/topic/show?id=569c9382389' target=_blank style='color:#2F92EE;'>#输血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93823, encryptionId=569c9382389, topicName=输血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Mar 23 05:16:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517614, encodeId=a480151e614d0, content=<a href='/topic/show?id=e8f46222188' target=_blank style='color:#2F92EE;'>#根治性切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62221, encryptionId=e8f46222188, topicName=根治性切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343211090953, createdName=12498f6em10暂无昵称, createdTime=Sat Mar 23 05:16:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586002, encodeId=392e1586002fb, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Mar 23 05:16:00 CST 2013, time=2013-03-23, status=1, ipAttribution=)]
    2013-03-23 jeanqiuqiu

相关资讯

卫生部印发结、直肠癌相关临床路径(附下载)

温家宝总理于2010年至2012年,连续3年在《政府工作报告》中提出:开展提高农村居民重大疾病医疗保障水平工作,将儿童白血病、先天性心脏病、重性精神病、艾滋病机会感染、尿毒症、结肠癌、直肠癌、胃癌等20种重大疾病纳入保障和救助试点范围。      继胃癌治疗相关6个临床路径制定、发布后,卫生部组织有关专家,结合我国医疗实际,研究制定了结肠癌、直

卫生部继发布乳腺癌相关临床路径

       为进一步深化医药卫生体制改革,保障提高农村居民重大疾病医疗保障水平工作顺利推进。卫生部组织有关专家,结合我国医疗实际,先后制定了各项肿瘤相关的临床路径,继胃癌治疗相关临床路径、结肠癌、直肠癌相关临床路径发布之后,乳腺癌相关的4项临床路径也已经颁布。      &nb

治疗结直肠疾病:机械人辅助的优于常规腹腔镜手术

    一项最新的荟萃分析研究指出,与传统腹腔镜手术(CLS)相比,机器人辅助的腹腔镜手术(RALS)与估计失血量降低和术中转换术式的发生率降低有关,而两者在并发症发生率和手术成功的替代指标方面无显著差异。也就是说,在治疗结直肠疾病,尤其是直肠癌方面,机械人辅助的腹腔镜手术优于常规腹腔镜手术,有着更好的应用前景。该论文于2012年7月3日在线发表于《肿瘤外科学年鉴》(Annals&nb

Ann Surg Oncol:直肠癌术前放(化)疗可损伤患者肛肠功能

        术前放(化)疗(pR(C)T)可显著降低患者局部复发风险,因而被推荐用于II/II期直肠癌患者。然而,这类多模式治疗方法可能与后期不良事件存在关联。为了确定pR(C)T对肛肠功能、性功能以及排尿功能的长期影响,德国慕尼黑工业大学的Martin Loos博士等人进行了一项系统性考察与荟萃分析。该文发表于2012年12月27日在线出版的《外科肿瘤学年鉴》(An

Lancet Oncology:氟尿嘧啶+奥沙利铂综合疗法或提高晚期直肠癌完全缓解率

  一项来自德国直肠癌研究小组的最新研究指出,在改良了的基于氟尿嘧啶(5-Fu)的综合疗法中加入奥沙利铂(OX)是可行的,并且,与标准治疗方法相比,这种方法可使更多患者达到完全病理缓解。然而,还需更长时间的随访以便评估患者的无病生存率。该论文于2012年7月发表于《柳叶刀·肿瘤》(The Lancet Oncology)杂志。   术前放化疗、全直肠系膜切除术和应用氟尿嘧啶行

慢性便秘易患直肠癌

  根据对一个美国大型回顾性索赔数据库资料的分析,慢性便秘可能使患者更易发生结直肠癌和良性肿瘤。   澳大利亚新南威尔士州纽卡斯尔大学的Nicholas Talley博士报告,该研究纳入1999年1月~2011年9月期间至少2次被诊断为慢性便秘(间隔60~365天)的年龄≥18岁的成年患者。排除肠易激综合征或腹泻患者,以及在首次诊断为便秘后至少12个月未继续参与健康计划的患者。对照受试者为观察期

Baidu
map
Baidu
map
Baidu
map